Compare MGY & ARQT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | MGY | ARQT |
|---|---|---|
| Founded | 2017 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Oil & Gas Production | Biotechnology: Pharmaceutical Preparations |
| Sector | Energy | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 4.0B | 3.3B |
| IPO Year | 2017 | 2020 |
| Metric | MGY | ARQT |
|---|---|---|
| Price | $21.89 | $29.59 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 11 | 7 |
| Target Price | ★ $25.20 | $24.83 |
| AVG Volume (30 Days) | ★ 2.2M | 1.8M |
| Earning Date | 02-17-2026 | 10-28-2025 |
| Dividend Yield | ★ 2.74% | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 1.80 | N/A |
| Revenue | ★ $1,320,826,000.00 | $317,929,000.00 |
| Revenue This Year | $1.07 | $85.51 |
| Revenue Next Year | $2.41 | $30.74 |
| P/E Ratio | $12.17 | ★ N/A |
| Revenue Growth | 0.68 | ★ 129.21 |
| 52 Week Low | $19.09 | $11.13 |
| 52 Week High | $26.84 | $31.77 |
| Indicator | MGY | ARQT |
|---|---|---|
| Relative Strength Index (RSI) | 42.77 | 56.35 |
| Support Level | $21.53 | $27.71 |
| Resistance Level | $22.28 | $30.26 |
| Average True Range (ATR) | 0.42 | 1.02 |
| MACD | -0.02 | -0.24 |
| Stochastic Oscillator | 17.75 | 74.59 |
Magnolia Oil & Gas Corp is an independent oil and natural gas company engaged in the acquisition, development, exploration, and production of oil, natural gas, and natural gas liquid (NGL) reserves. The company's oil and natural gas properties are located in Karnes County and the Giddings area in South Texas, where the Company targets the Eagle Ford Shale and Austin Chalk formations. Its objective is to generate stock market value over the long term through consistent organic production growth, high full-cycle operating margins, and an efficient capital program with short economic paybacks. The company's operating segment is acquisition, development, exploration, and production of oil and natural gas properties located in the United States.
Arcutis Biotherapeutics Inc is a medical dermatology company. It is developing treatments for patients with immune-mediated dermatological diseases and conditions. It is leveraging recent advances in immunology and inflammation to develop differentiated therapies against biologically validated targets to solve persistent treatment challenges in serious diseases of the skin. The company's product candidate ZORYVE roflumilast cream, has completed pivotal Phase 3 clinical trials in plaque psoriasis, demonstrating symptomatic improvement and favorable tolerability in this population.